Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

the project is an estimated RMB 50 million (approximately $7.1 million).

2008 Outlook

"We recently obtained the patent and exclusive production rights to a new asthma drug, Laevo-Bambutero, which we plan to launch in 2012 after we receive approval from the SFDA. We currently have fourteen drugs for which we are seeking SFDA approval, and plans for manufacturing a number of new pharmaceutical products," said Dr. Liu. "In 2008, we expect strong revenue growth to be led by our distribution of pharmaceutical products manufactured by third-parties and our best selling branded products. For the full year 2008, because of our growing distribution network, we remain confident that we will meet our 'make good' net income target of $13.1 million."

"As part of our longer term growth strategy, we began the process of acquiring land use rights on which to construct a product development and manufacturing facility that will allow us produce a wide range of new pharmaceutical products. We hope to have the facility completed by the end of 2010. However, we may adjust the time line depending on our availability of working capital and external funds. We obtained the land use rights at a favorable price and may be able to monetize a portion of them in the future."

Conference Call

Lotus' management will host a conference call at 10:00 a.m. Eastern Time on Monday, August 18, 2008 to discuss results for the quarter ended June 30, 2008. To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 888- 481-7939. International callers should call 617-847-8707. The Conference Pass Code is 306 650 22.

Replay of the conference call will be available from 12 p.m. Eastern Time on Monday, August 18 for fourteen days. To access the replay, call 888-286- 8010. International callers should call 617-801-6888. The Conference Pass Code is 939 152 01.

Use of Non-GAAP Financi
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... trends and segments with highest potential revenues Do ... Visiongain,s updated report gives you revenue predictions for ... ahead. For those therapies you find financial data, ... new analysis you get sales forecasts to 2024 ...
(Date:9/30/2014)... 30, 2014 Nematicide is a type ... are microscopic parasitic roundworms, found in massive quantities ... plants and animals. Nematicides have tended to be ... promoting migration through the soil. A single gram ... nematodes. With more than 10,000 species classified, they ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... , , , ... the world,s leading research and advisory firms focusing on pharmaceutical ... lost substantial patient share in second- and third-line therapy since ... is most likely attributed to the publication of the ENHANCE ...
... , EMERYVILLE, Calif., Aug. 12 Neurobiological Technologies, ... it has entered into an agreement to terminate its license ... Medical Center Corporation (CMCC). Pursuant to the termination of ... final payment to NTI in satisfaction of all its royalty ...
... ... and lost each month, though the average of new jobs in the industry remains at 20,000 ... the U.S. However, companies ancillary to health care, such as insurers, are feeling the economic pinch ... (Vocus) August 12, ...
Cached Biology Technology:Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 3Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 3The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 4
(Date:9/30/2014)... in German . ... expensive foods in the world. Because they grow underground, people ... distinctive smell of truffles is not only of interest to ... direction of the Goethe University Frankfurt have discovered that the ... which are trapped inside truffle fruiting bodies. , White truffles ...
(Date:9/30/2014)... to know what goes wrong with your muscles because of ... what "normal" actually is. That,s where a new research report ... FASEB Journal comes in. In the report, a ... molecules that can help scientists "see" which genes are active ... found never-before-detected gene activity and that men have approximately 400 ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Scientists identify which genes are active in muscles of men and women 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... is the first handbook of its kind, introducing ... microcirculation. Clearly structured throughout, this book is ... on microcirculation imaging. , Author Professor Martin J. ... explores everything from basic research to medical applications. ...
... Bethesda, MD FASEB MARC (Maximizing Access to Research ... the 2012 Genetics Society of America (GSA) Yeast Genetics ... 31 August 5, 2012. These awards are ... postdoctorates and scientists into the mainstream of the basic ...
... from the fields of social, biological and medical science ... to discuss how they can cooperate to improve our ... influence how our genetic inheritance is expressed (epigenetics). This ... epigenetic changes have for such key social policy issues ...
Cached Biology News:World experts meet in Edinburgh to consider how life experiences impact on our genes 2
... is an aqueous-based mounting medium designed ... sections. Gel/Mount is especially recommended when ... or FluoroBlue. It can also be ... as fluorescein (FITC), Rhodamine (TMRITC) and ...
... - Fixation medium Reagent B - Permeabilisation ... fixing cells in suspension with Reagent A ... B. This procedure gives antibodies access to ... characteristics of the cells intact. Specific formulations ...
...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Biology Products: